



19 September 2011

Evgen set to develop pharmaceutical for patients with early stage prostate cancer

**Evgen Limited
("Evgen" or the "Company")**

And

PharmAgra labs Inc and Lalilab Inc

Having recently secured investment from a UK venture capital syndicate, Evgen (www.evgen.com) has exercised its option and entered into a world-wide exclusive license agreement to develop Sulforadex® as a pharmaceutical. Sulforadex® has enormous potential in the prevention and treatment of prostate cancer and other cancers.

Prostate cancer is becoming one of the world's leading health issues with 80% of men developing the condition within their lives. This increasing incidence is linked to more widespread screening; a phenomenon that has created a substantial population of men who have been told they have an indolent form of the disease where "watchful waiting" is the preferred course of action. For this group of patients, a treatment that could retard future disease progression (30% measurably advance over one year) with minimal side effects could improve quality of life; prevent complications and lower treatment costs. Unfortunately, there is no drug on the market that successfully addresses this problem.

There are many hundreds of scientific studies that have focused on the anti-cancer activity of a molecule called sulforaphane – a molecule that can, in some circumstances, be produced in varying amounts upon the consumption of sufficient quantities of cruciferous vegetables such as broccoli. Since the beginning of the year alone, there have been over 80 published scientific studies confirming the therapeutic potential of this molecule. However, sulforaphane has hitherto never been a viable drug candidate because it is inherently unstable, decomposing rapidly in open air within minutes to hours.

Sulforadex® is a unique *stabilised sulforaphane*, extending shelf life and utility from hours to years, making pharmaceutical applications viable for the first time. The composition, based upon a synthetic sulforaphane encapsulated within a sugar structure called an alpha-cyclodextrin, represents a material development in realising the clinical potential as extolled by a substantial body of scientific literature.

PharmAgra Labs Inc and Lalilab Inc retain the rights to develop the patented stabilised sulforaphane technology for topical applications; focusing on skin disease therapeutics and cosmetics.

Commenting on the agreement, Chief Executive, Dr Stephen Franklin said:

"We are tremendously excited to be working with PharmAgra Labs and Lalilab Inc and to be responsible for pioneering the clinical development of this exciting molecule. Our preclinical programme will complete in the next year and then we intend to initially target men with indolent prostate cancer. However, Sulforadex® has much wider potential in the treatment of more advanced cancers; most likely in combination therapies with existing treatment regimes. This is an area where we will be proactively pursuing strategic partnerships".

Speaking on behalf of PharmAgra Labs Inc and Lalilab Inc, Roger Frisbee, Co-President of PharmAgra Labs Inc, said:

"PharmAgra, Lalilab and Evgen share a common vision of the commercial potential of a stabilized sulforaphane. Combining our chemistry and manufacturing skills, together with Evgen's clinical development expertise, we are confident that we could be embarking on a drug development program with a much lower risk of clinical failure than is typical for a new chemical or biological entity".

-END-

For further information please contact:

Evgen Limited

Dr Stephen Franklin, Chief Executive

+44 7710 348774

Notes:

Evgen Limited

Evgen (www.evgen.com) was founded by serial entrepreneur Dr Stephen Franklin in 2008. The Company is dedicated to commercialising the clinical potential of sulforaphane (and related compounds), a molecule of botanical origin with an exciting and compelling body of scientific literature supporting multiple human healthcare benefits. The Company holds proprietary technology that enables sulforaphane, for the first time, to be synthesised and then subsequently stabilised for pharmaceutical application.

PharmAgra Labs Inc

PharmAgra Labs, Inc. (www.pharmagra.com) is a privately held company located in Brevard, NC USA. Established in 1998, PharmAgra provides contract R&D services in organic and medicinal chemistry in addition to conducting their own proprietary research. The company also conducts cGMP production of Active Pharmaceutical Ingredients for use in Clinical Trials.

Lalilab Inc

Lalilab Inc (www.lalilab.com) is a privately held company located in Durham, NC USA. Established in 1996, Lalilab manufactures, sources and develops high quality raw materials for the pharmaceutical, dietary supplement and cosmetic industry.